Resistant Hypertension in Adults: Evaluation and Treatment

Sean P. Haley, MD, MPH
Scott Bragg, PharmD
Leah Stem, MD, MS

American Family Physician. 2026;113(1):43-50.

Author disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

Difficult-to-control hypertension is a common issue in primary care. Resistant hypertension is defined as a blood pressure (BP) measurement above goal despite the use of maximum or optimal dosages of three antihypertensive agents, including a diuretic. Before diagnosing resistant hypertension, family physicians should evaluate patients with difficult-to-control BP for comorbid conditions, medication nonadherence, white coat hypertension, secondary hyper-tension, and suboptimal therapy. Attention should be focused on ensuring accurate BP measurement technique in the office and confirmatory BP monitoring at home. Management of resistant hypertension should include evidence-based lifestyle interventions, adjustment of plans for social factors, and individualized medication regimens. A dihydropyridine calcium channel blocker, an angiotensin receptor blocker or angiotensin-converting enzyme inhibitor, and a thiazide diuretic should be part of the initial three-drug regimen. Therapy may be suboptimal if preferred antihypertensives are not used, medications are inadequately dosed, lifestyle factors are not addressed, comorbidities are improperly treated, or social factors are not recognized. In patients with resistant hypertension, a mineralocorticoid receptor antagonist is the preferred fourth-line option. Other antihypertensives to improve BP control should be considered based on patient factors and shared decision-making. For patients who are unable to tolerate medications or achieve adequate BP control, referral for interventional options (eg, renal sympathetic denervation, carotid baroreceptor amplification) should be considered.

SEAN P. HALEY, MD, MPH, is an associate professor in the Department of Family Medicine at Medical University of South Carolina in Charleston.

SCOTT BRAGG, PharmD, is an associate professor in the Department of Clinical Pharmacy and Outcomes Sciences and the Department of Family Medicine at Medical University of South Carolina in Charleston.

LEAH STEM, MD, MS, is an assistant professor in the Department of Family Medicine at Medical University of South Carolina in Charleston.

Address correspondence to Sean P. Haley, MD, MPH, at haleys@musc.edu.

Author disclosure: No relevant financial relationships.

  1. 1.Fryar CD, Kit B, Carroll MD, et al. Hypertension prevalence, treatment, and control among adults: Los Angeles County and the United States, 2015–2018. NCHS Health E-Stats. November 2023.
  2. 2.Calhoun DA, Jones D, Textor S, et al.; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-e526.
  3. 3.Carey RM, Sakhuja S, Calhoun DA, et al. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension. 2019;73(2):424-431.
  4. 4.Carey RM, Calhoun DA, Bakris GL, et al.; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53-e90.
  5. 5.Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248.
  6. 6.Unger T, Borghi C, Charchar F, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334-1357.
  7. 7.Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA. 2014;311(21):2216-2224.
  8. 8.Coles S, Fisher L, Lin KW, et al. Blood pressure targets in adults with hypertension: a clinical practice guideline from the AAFP. Am Fam Physician. 2022;106(6) ): online.
  9. 9.Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med. 2019;179(3):351-362.
  10. 10.Ishigami J, Charleston J, Miller ER, et al. Effects of cuff size on the accuracy of blood pressure readings: the Cuff(SZ) randomized crossover trial. JAMA Intern Med. 2023;183(10):1061-1068.
  11. 11.Ozone S, Shaku F, Sato M, et al. Comparison of blood pressure measurements on the bare arm, over a sleeve and over a rolled-up sleeve in the elderly. Fam Pract. 2016;33(5):517-522.
  12. 12.Pickering TG, Hall JE, Appel LJ, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142-161.
  13. 13.Liu H, Zhao D, Sabit A, et al. Arm position and blood pressure readings: the ARMS Crossover Randomized Clinical Trial. JAMA Intern Med. 2024;184(12):1436-1442.
  14. 14.Krist AH, Davidson KW, Mangione CM, et al.; US Preventive Services Task Force. Screening for hypertension in adults: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2021;325(16):1650-1656.
  15. 15.Guirguis-Blake JM, Evans CV, Webber EM, et al. Screening for hypertension in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021;325(16):1657-1669.
  16. 16.Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension. 2019;73(5):e35-e66.
  17. 17.Stergiou GS, Palatini P, Parati G, et al.; European Society of Hypertension Council and the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293-1302.
  18. 18.Groenland EH, Bots ML, Visseren FLJ, et al. Number of measurement days needed for obtaining a reliable estimate of home blood pressure and hypertension status. Blood Press. 2022;31(1):100-108.
  19. 19.Shimbo D, Abdalla M, Falzon L, et al. Studies comparing ambulatory blood pressure and home blood pressure on cardiovascular disease and mortality outcomes: a systematic review. J Am Soc Hypertens. 2016;10(3):224-234.e17.
  20. 20.Giao DM, Col H, Kwapong FL, et al. Supine blood pressure and risk of cardiovascular disease and mortality. JAMA Cardiol. 2025;10(3):265-275.
  21. 21.Atzema CL, Wong A, Masood S, et al. The characteristics and outcomes of patients who make an emergency department visit for hypertension after use of a home or pharmacy blood pressure device. Ann Emerg Med. 2018;72(5):534-543.
  22. 22.Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245-1254.
  23. 23.Charles L, Triscott J, Dobbs B. Secondary hypertension: discovering the underlying cause. Am Fam Physician. 2017;96(7):453-461.
  24. 24.Chen R, Suchard MA, Krumholz HM, et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension. 2021;78(3):591-603.
  25. 25.Bangalore S, Fakheri R, Toklu B, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc. 2016;91(1):51-60.
  26. 26.Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3):290-300.
  27. 27.Chow CK, Atkins ER, Hillis GS, et al.; QUARTET Investigators. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398(10305):1043-1052.
  28. 28.Bennett A, Chow CK, Chou M, et al. Efficacy and safety of quarter-dose blood pressure-lowering agents: a systematic review and meta-analysis of randomized controlled trials. Hypertension. 2017;70(1):85-93.
  29. 29.Lovegrove E, Robson J, McGettigan P. Pregnancy protection and pregnancies in women prescribed ACE inhibitors or ARBs: a cross-sectional study in primary care. Br J Gen Pract. 2020;70(700):e778-e784.
  30. 30.Farahi N, Oluyadi F, Dotson AB. Hypertensive disorders of pregnancy. Am Fam Physician. 2024;109(3):251-260.
  31. 31.Lenz TL, DeSimone EM, Pomeroy JM. Implementing lifestyle medicine in hypertensive patients. US Pharm. 2011;36(2):44-50.
  32. 32.Chapman N, Dobson J, Wilson S, et al.; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839-845.
  33. 33.Williams B, MacDonald TM, Morant S, et al.; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068.
  34. 34.Chung EYM, Ruospo M, Natale P, et al. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020(10):CD007004.
  35. 35.Agarwal R, Rossignol P, Budden J, et al. Patiromer and spironolactone in resistant hypertension and advanced CKD: analysis of the randomized AMBER trial. Kidney360. 2021;2(3):425-434.
  36. 36.UpToDate Lexidrug. Accessed November 5, 2025. https://online.lexi.com
  37. 37.Schlaich MP, Bellet M, Weber MA, et al.; PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927-1937.
  38. 38.US Food and Drug Administration. Tryvio prescribing information. March 2024. Accessed October 21, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217686s000lbl.pdf
  39. 39.Wong GWK, Laugerotte A, Wright JM. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension. Cochrane Database Syst Rev. 2015(8):CD007449.
  40. 40.Viera AJ, Hinderliter AL. Evaluation and management of the patient with difficult-to-control or resistant hypertension. Am Fam Physician. 2009;79(10):863-869.
  41. 41.Alviar CL, Devarapally S, Nadkarni GN, et al. Efficacy and safety of dual calcium channel blockade for the treatment of hypertension: a meta-analysis. Am J Hypertens. 2013;26(2):287-297.
  42. 42.Jain AK, Hiremath A, Michael R, et al. Clonidine and guanfacine in hypertension. Clin Pharmacol Ther. 1985;37(3):271-276.
  43. 43.Wilson MF, Haring O, Lewin A, et al. Comparison of guanfacine versus clonidine for efficacy, safety and occurrence of withdrawal syndrome in step-2 treatment of mild to moderate essential hypertension. Am J Cardiol. 1986;57(9):43E-49E.
  44. 44.Acelajado MC, Hughes ZH, Oparil S, et al. Treatment of resistant and refractory hypertension. Circ Res. 2019;124(7):1061-1070.
  45. 45.Oparil S, Calhoun DA. Managing the patient with hard-to-control hypertension. Am Fam Physician. 1998;57(5):1007-1014.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.